DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions
Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Poorvi Somaiya(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Lynne Uhl(Hadassah Medical Center), Ilene Galinsky(Dana-Farber Cancer Institute), Katarina Luptakova(Tesaro (United States)), Donald Küfe(Dana-Farber Cancer Institute), Malgorzata McMasters(Beth Israel Deaconess Medical Center), Richard M. Stone(Dana-Farber Cancer Institute), Mary Paty Bryant(Beth Israel Deaconess Medical Center), Salvia Jain(Broad Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Emma Logan(Beth Israel Deaconess Medical Center), David P. Steensma(Harvard University), Dina Stroopinsky(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Donna Neuberg(Otsuka (Japan)), Kristen Palmer(Beth Israel Deaconess Medical Center), Aya Sato-DiLorenzo(Beth Israel Deaconess Medical Center)
Cited by 6
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k